Evaluating Moderating Effects of Sleep Disturbance and Irritability in the Acute Treatment Phase
irritability
SEPARATION
Compared to placebo, lurasidone treatment significantly improved “decreased need for sleep” (YMRS item 4) (Cohen’s The baseline decreased need for sleep predicted a change in CDRS-R total score at the week 6 endpoint with lurasidone (Change in YMRS total (The presence of “decreased need for sleep” (YMRS item 4 > 0) at study baseline was associated with greater improvement in YMRS total score (Cohen’s The presence of “decreased need for sleep” (YMRS item 4 > 0) at study baseline was associated with greater improvement in CGAS (Cohen’s The presence of “decreased need for sleep” (YMRS item 4) and/or “irritability” (YMRS item 5) at study baseline moderated the effect of lurasidone (The symptom network structure at the week 6 study endpoint showed a separation of the CDRS-R and YMRS items forming two distinct symptom clusters, while the direct links between “decreased need for sleep” (YMRS item 4) and “difficulty with sleep” (CDRS-R item 4) and between “irritability” YMRS item 5 and CDRS-R item 8 remained (see Graphical Abstract).